Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Reinforces its proactive commitment to safeguarding sensitive client data across its global operations.
March 10, 2026
By: Charlie Sternberg
Associate Editor
Symeres has been awarded ISO/IEC 27001 certification, the internationally recognized standard for information security management systems (ISMS). This certification reinforces the company’s proactive commitment to safeguarding sensitive client data across its global operations.
“Cybersecurity is no longer a back-office issue; it is central to the success of every client program,” said Gabriella Gentile, Chief Operating Officer at Symeres. “Our ISO 27001 certification gives clients, from biotech startups to large pharmaceutical companies, the assurance that their proprietary data, often the ‘crown jewels’ of development, is protected within a robust and continuously improving security framework.”
While Symeres has long operated with strong internal protocols, the decision to pursue formal certification arose from a rising volume of security questionnaires from clients, financial institutions, and regulators.
For many large pharmaceutical companies, information security assessments are now a standard part of onboarding. ISO 27001 certification allows Symeres to address the majority of these requirements upfront, significantly streamlining due diligence processes. By reducing administrative friction, project teams can focus more quickly on what matters most: advancing client programs and delivering scientific impact.
Guillaume Jetten, CEO at Symeres, said: “In today’s environment, ISO 27001 is a non-negotiable foundation for doing business with large pharmaceutical companies and innovative biotechs. Achieving this certification cements Symeres’ status as a leading global CDMO operating with full transparency and accountability.”
With ISO 27001 in place, Symeres is positioned to support the needs of both established pharmaceutical clients and smaller biotechs that may rely on its expertise to navigate complex data governance. The certification also supports broader industry compliance efforts, including the EU’s NIS2 Directive, which identifies healthcare organizations as vital operators.
Symeres is progressing with the rollout of ISO 27001 certification across its sites globally, with completion targeted before the end of the year. This phased implementation ensures consistent standards across the Group while maintaining operational continuity.
Enter the destination URL
Or link to existing content
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !